11/7
04:18 pm
atha
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates [Yahoo! Finance]
High
Report
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates [Yahoo! Finance]
11/7
04:05 pm
atha
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Medium
Report
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
10/22
07:00 am
atha
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
High
Report
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
9/19
07:58 am
atha
Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $0.50 price target on the stock, down previously from $5.00.
Low
Report
Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $0.50 price target on the stock, down previously from $5.00.
9/17
09:00 am
atha
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
Medium
Report
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
9/4
08:54 am
atha
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks [Yahoo! Finance]
High
Report
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks [Yahoo! Finance]
9/4
08:37 am
atha
Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at Rodman & Renshaw from a "buy" rating to a "neutral" rating.
High
Report
Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at Rodman & Renshaw from a "buy" rating to a "neutral" rating.
9/4
07:38 am
atha
Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.
High
Report
Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.
9/4
07:38 am
atha
Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at JMP Securities from an "outperform" rating to a "market perform" rating.
High
Report
Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at JMP Securities from an "outperform" rating to a "market perform" rating.
9/3
04:06 pm
atha
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease [Yahoo! Finance]
High
Report
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease [Yahoo! Finance]
9/3
04:01 pm
atha
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
High
Report
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
8/23
10:57 am
atha
Are Medical Stocks Lagging Athira Pharma (ATHA) This Year? [Yahoo! Finance]
Medium
Report
Are Medical Stocks Lagging Athira Pharma (ATHA) This Year? [Yahoo! Finance]